Cytek Biosciences Inc Total Assets
Cytek Biosciences Inc total assets. Based on the latest financial reports, Cytek Biosciences Inc (CTKB) holds total assets worth $449.11 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Cytek Biosciences Inc stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Cytek Biosciences Inc (2019–2025)
Total assets of Cytek Biosciences Inc from 2019 to 2025. This chart illustrates how Cytek Biosciences Inc's total assets have evolved over time, based on quarterly financial data. See Cytek Biosciences Inc (CTKB) share price today for real-time trading data and today's change.
Cytek Biosciences Inc - Asset Composition Analysis
Cytek Biosciences Inc Total Assets Breakdown (December 2025)
Cytek Biosciences Inc total assets breakdown as of December 2025. Cytek Biosciences Inc's total assets of $449.11 Million consist of 84.9% current assets and 15.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.7% |
| Accounts Receivable | $72.13 Million | 15.6% |
| Inventory | $48.43 Million | 10.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $16.82 Million | 3.6% |
| Goodwill | $16.70 Million | 3.6% |
Asset Composition Trend (2019–2025)
This chart illustrates how Cytek Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore CTKB working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cytek Biosciences Inc's current assets represent 84.9% of total assets in 2025, a decrease from 96.3% in 2019.
- Cash Position: Cash and equivalents constituted 19.7% of total assets in 2025, down from 42.8% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 15.6% of total assets.
Cytek Biosciences Inc Competitors by Total Assets
Key competitors of Cytek Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥916.43 Million |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
Applied BioCode
TW:6598
|
Taiwan | NT$1.03 Billion |
|
Oncosil Medical Ltd
AU:OSL
|
Australia | AU$7.13 Million |
|
Sequana Medical NV
BR:SEQUA
|
Belgium | €14.57 Million |
|
Cleo Diagnostics Ltd
AU:COV
|
Australia | AU$9.96 Million |
|
Radiant Innovation
TWO:3373
|
Taiwan | NT$859.52 Million |
|
MedX Health Corp
V:MDX
|
Canada | CA$1.26 Million |
Cytek Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.69 | 5.62 | 7.70 |
| Quick Ratio | 4.07 | 4.95 | 6.76 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $298.37 Million | $312.81 Million | $188.77 Million |
Cytek Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Cytek Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.81 |
| Latest Market Cap to Assets Ratio | 1.28 |
| Asset Growth Rate (YoY) | -7.6% |
| Total Assets | $461.54 Million |
| Market Capitalization | $588.89 Million USD |
Valuation Analysis
Above Book Valuation: The market values Cytek Biosciences Inc's assets above their book value (1.28x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Cytek Biosciences Inc's assets decreased by 7.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cytek Biosciences Inc (2019–2025)
The table below shows the annual total assets of Cytek Biosciences Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $461.54 Million | -7.60% |
| 2024-12-31 | $499.50 Million | +1.02% |
| 2023-12-31 | $494.46 Million | -4.82% |
| 2022-12-31 | $519.48 Million | +12.12% |
| 2021-12-31 | $463.31 Million | +110.61% |
| 2020-12-31 | $219.98 Million | +212.64% |
| 2019-12-31 | $70.36 Million | -- |
About Cytek Biosciences Inc
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies usin… Read more